Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

BioNTech and Bristol Myers Squibb announced interim Phase 2 data from the ROSETTA Lung-02 trial showing that their investigational bispecific immunomodulator pumitamig combined with chemotherapy demonstrated encouraging anti-tumor activity in first-line non-small cell lung cancer, with confirmed objective response rates of 63.6% in non-squamous and 72.7% in squamous subtypes at the lower dose. The drug showed consistent efficacy across PD-L1 expression levels with a manageable safety profile, and is advancing through a comprehensive Phase 3 development program.

05/30/2026, 2:15 PM • GlobeNewswire

Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs

BioNTech and Bristol Myers Squibb announced interim results from the ROSETTA Lung-02 Phase 2/3 study showing that their bispecific PD-L1xVEGF-A immunomodulator candidate Pumitamig demonstrated encouraging anti-tumor activity in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC). The drug showed confirmed objective response rates of 63.6% in non-squamous and 72.7% in squamous NSCLC subtypes at the lower dose, with consistent efficacy across all PD-L1 expression levels. The companies are advancing a comprehensive global Phase 3 development program with multiple ongoing trials.

05/30/2026, 2:15 PM • GlobeNewswire

BioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung

BioNTech will present clinical data at the 2026 ASCO Annual Meeting on late-stage oncology pipeline programs, including positive Phase 2 data from ROSETTA Lung-02 for Pumitamig (in combination with chemotherapy for non-small cell lung cancer) and overall survival data for Gotistobart in platinum-resistant ovarian cancer. The company is advancing a diversified portfolio with over 25 Phase 2/3 clinical trials, including 13 ongoing registration-relevant studies.

05/22/2026, 5:00 AM • GlobeNewswire

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

BioNTech will present clinical data at ASCO 2026 showing encouraging anti-tumor activity for pumitamig in combination with chemotherapy across multiple cancer types, and positive overall survival data for gotistobart in platinum-resistant ovarian cancer. The company is advancing 25+ Phase 2/3 trials including 13 pivotal trials across its diversified oncology pipeline.

05/22/2026, 5:00 AM • GlobeNewswire

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demonstrated by COVID-19 vaccine developers. Better opportunities exist in established vaccine makers with strong pipelines or broad market index funds.

05/13/2026, 1:15 PM • The Motley Fool

Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors.

Bristol Myers Squibb trades at $55.67 with concerns about upcoming patent cliffs for its top-selling drugs Opdivo and Eliquis. However, the company's newer drug portfolio and promising pipeline, including Milvexian and Pumitamig, could offset these losses. Trading at 9x forward earnings versus the healthcare sector average of 16.8x, the stock appears attractively valued for long-term investors seeking both growth and a 4.5% dividend yield.

05/11/2026, 9:15 PM • The Motley Fool

BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

BioNTech stock declined 3% after reporting Q1 revenues of €118.1 million, missing consensus estimates due to lower COVID-19 vaccine sales. The company posted a net loss of €531.9 million and announced a major restructuring plan involving the closure of manufacturing sites in Germany and Singapore, targeting €500 million in annual cost savings by 2029. The company maintained its FY2026 revenue guidance of €2-2.3 billion.

05/05/2026, 12:18 PM • Benzinga

Moderna's Legal Hit Steals Spotlight From Strong Sales

Moderna shares fell 2.05% on Friday despite beating revenue expectations with $389 million (vs. $227.97M consensus) and reporting a narrower adjusted loss of $1.18 per share. The decline was driven by a $2.22 per share litigation settlement charge. The company reiterated 2026 revenue growth guidance of up to 10% and announced progress on its H5 pandemic flu vaccine candidate with a Phase 3 trial launch.

05/01/2026, 10:44 AM • Benzinga

Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor

Inventiva announced the recruitment of three new senior executives: Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. These appointments strengthen the company's leadership team ahead of the anticipated Phase 3 top-line data readout for lanifibranor in Q4 2026. Previous CFO Jean Volatier will transition to EVP Finance & Corporate Social Responsibility.

04/22/2026, 4:00 PM • GlobeNewswire

Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight

Over 100 pharmaceutical companies are competing to develop 120+ pipeline drugs for non-small cell lung cancer (NSCLC), with approximately 30+ drugs in late-stage development. The competitive landscape is driven by precision oncology advances, including next-generation targeted agents and immunotherapy combinations. Recent FDA approvals and designations highlight innovation in treating EGFR-mutated, ALK-positive, and other biomarker-selected NSCLC populations.

04/16/2026, 1:00 PM • GlobeNewswire

Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive Officer

Anaveon, a late-stage preclinical biotech company focused on immune system reprogramming, announced the appointment of Thaminda Ramanayake as CEO. Ramanayake brings over 20 years of biopharmaceutical leadership experience, including roles at CureVac, Sanofi, BioMarin, and Amgen. He will lead Anaveon's advancement of its immunology pipeline toward clinical development, with ANV200 as the lead asset for T cell depletion in autoimmune and inflammatory diseases.

03/23/2026, 5:00 AM • GlobeNewswire

BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls

BioNTech shares plummeted 17.67% after the company issued weaker-than-expected 2026 revenue guidance of $2.2-$2.5 billion, citing normalized Covid vaccine sales. Co-founders Ugur Sahin and Ozlem Tureci plan to exit by end of 2026 to launch a new mRNA firm, while the company pivots toward capital-intensive oncology development. Despite maintaining a strong €16 billion cash position, investors are concerned about leadership continuity and the multi-year investment phase before oncology revenue contributions materialize.

03/10/2026, 3:39 PM • Benzinga

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Law firm Johnson Fistel is investigating BioNTech SE following the company's disclosure of declining COVID-19 vaccine demand, a net loss of €305 million in Q4 2025, and the planned departure of founders Uğur Şahin and Özlem Türeci by end of 2026. The investigation examines whether BioNTech complied with federal securities laws, with shareholders invited to join the investigation.

03/10/2026, 2:48 PM • GlobeNewswire

BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture

BioNTech shares fell 14.25% in premarket trading after co-founders Ugur Sahin and Özlem Türeci announced plans to transition to a new mRNA venture by end of 2026. The company also lowered 2026 sales guidance to $2.33-$2.68 billion due to declining COVID-19 vaccine demand, though it expects multiple late-stage oncology data readouts in 2026.

03/10/2026, 8:40 AM • Benzinga

Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars

Moderna reached a $950 million settlement agreement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving litigation related to its COVID-19 vaccine Spikevax and mRESVIA product. The settlement clears a major legal overhang, allowing the company to focus on future growth. Moderna expects to end 2026 with $4.5-5 billion in cash and aims for breakeven in 2028. The stock surged 8.85% in premarket trading as the settlement value was better than investors' worst-case fears.

03/04/2026, 8:14 AM • Benzinga